Acadia’s schizophrenia drug fails study end point
Neither dose of ACP-104 demonstrated improved efficacy as compared to placebo. There was no clinically significant decrease in neutrophil counts in the study drug arms. The ACP-104 trial
Novartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies.
Delivered via intravitreal injection, the ophthalmic indications for Trivaris include sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. These are inflammatory conditions that